Orient EuroPharma Co., Ltd. Stock

Equities

4120

TW0004120001

Food Processing

End-of-day quote Taipei Exchange 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
42.75 TWD 0.00% Intraday chart for Orient EuroPharma Co., Ltd. +0.71% +9.90%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2022 4.73B 146M Sales 2023 4.59B 142M Capitalization 3.37B 104M
Net income 2022 -311M -9.59M Net income 2023 144M 4.44M EV / Sales 2022 1.33 x
Net Debt 2022 3.15B 97.22M Net Debt 2023 2.74B 84.47M EV / Sales 2023 1.33 x
P/E ratio 2022
-10.1 x
P/E ratio 2023
23.4 x
Employees -
Yield 2022 *
-
Yield 2023
2.57%
Free-Float 35.17%
More Fundamentals * Assessed data
Dynamic Chart
Regeneus Ltd announced that it expects to receive AUD 3.481164 million in funding from Zheng Yang Biomedical Technology Co., Ltd., Orient EuroPharma Co., Ltd. and other investors CI
Orient EuroPharma Co., Ltd. announced that it expects to receive TWD 300 million in funding CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Orient EuroPharma Co., Ltd. Appoints Jack Wang as Accounting Officer CI
Orient EuroPharma Co., Ltd. Appoints Jack Wang as Financial Officer CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Orient EuroPharma, OncoVent Sign License Deal MT
OncoVent Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
More news
1 week+0.71%
Current month+1.79%
1 month-3.28%
3 months+12.20%
6 months+8.50%
Current year+9.90%
More quotes
1 week
41.85
Extreme 41.85
43.45
1 month
40.30
Extreme 40.3
44.25
Current year
36.70
Extreme 36.7
45.80
1 year
35.65
Extreme 35.65
48.30
3 years
32.10
Extreme 32.1
48.30
5 years
32.10
Extreme 32.1
65.80
10 years
32.10
Extreme 32.1
104.00
More quotes
Managers TitleAgeSince
Chairman - -
Investor Relations Contact - -
Comptroller/Controller/Auditor - 20-12-31
Members of the board TitleAgeSince
Director/Board Member 64 02-12-31
Chairman - -
Director/Board Member - 22-06-29
More insiders
Date Price Change Volume
24-05-10 42.75 0.00% 28,015
24-05-09 42.75 0.00% 35,674
24-05-08 42.75 +1.18% 35,828
24-05-07 42.25 -1.05% 33,593
24-05-06 42.7 +0.59% 42,596

End-of-day quote Taipei Exchange, May 09, 2024

More quotes
Orient Europharma Co., Ltd. is principally engaged in the manufacture and distribution of nutritious healthcare products and medical cosmetic products, as well as western drugs. The Company operates nutritious healthcare products and medical cosmetic products segment, providing infant milk powders, nutritious products and functional healthcare products, as well as dermatological preparations, medical hair care series, organic skin care series and medical make-up products, among others; western drugs segment, providing products for cardiovascular diseases, cancer, blood diseases, diabetes, central nervous system diseases and asthma, among others.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW